Kisspeptin-10 vs Liraglutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Kisspeptin-10
Kisspeptin-10 is the active fragment of kisspeptin, a hormone that plays a crucial role in initiating puberty and regulating reproductive function. It acts upstream of GnRH in the hypothalamic-pituitary-gonadal axis.
Full details →Liraglutide
Liraglutide is a GLP-1 receptor agonist — a 31-amino acid peptide analog with 97% homology to native human GLP-1. FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). It was the first GLP-1 agonist approved specifically for obesity. Liraglutide has a shorter half-life than semaglutide (13 hours vs 7 days), requiring daily rather than weekly dosing.
Full details →Side-by-Side Comparison
| Aspect | Kisspeptin-10 | Liraglutide |
|---|---|---|
| Mechanism | Binds to KISS1R receptors in the hypothalamus, stimulating GnRH neurons to release GnRH. This triggers the downstream cascade of LH, FSH, and sex hormone production. | Liraglutide binds to the GLP-1 receptor, activating the same pathways as native GLP-1: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression. A C-16 fatty acid (palmitic acid) attached to Lys26 via a glutamic acid spacer enables albumin binding, extending the half-life from ~2 minutes (native GLP-1) to ~13 hours. Less potent albumin binding and shorter half-life compared to semaglutide necessitates once-daily dosing. |
| Typical Dosage | Research protocols vary widely. Studies have used IV boluses of 1-10mcg/kg or subcutaneous administration. Clinical applications still being developed. | For weight management (Saxenda): start at 0.6 mg daily for 1 week. Increase by 0.6 mg weekly until reaching 3.0 mg daily maintenance dose. For type 2 diabetes (Victoza): start at 0.6 mg daily for 1 week, increase to 1.2 mg. May increase to 1.8 mg if additional glycemic control is needed. |
| Administration | IV or subcutaneous injection. Has very short half-life requiring frequent administration or continuous infusion for sustained effects. | Subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites. Administer once daily at any time, independent of meals. Store pens refrigerated before first use; after first use, store at room temperature or refrigerated for up to 30 days. |
| Side Effects | Limited data. May cause flushing, increased heart rate, and changes in libido. Generally well-tolerated in studies. | Very common (>10%): nausea (up to 40%), diarrhea, constipation, vomiting, decreased appetite, dyspepsia, abdominal pain. Higher rate of daily GI symptoms compared to weekly GLP-1s due to daily dosing peaks. Common (1-10%): headache, dizziness, fatigue, injection site reactions, increased heart rate. |
| Best For |
Key Differences
Unique to Kisspeptin-10:
Unique to Liraglutide:
Detailed Analysis
Commonalities
Kisspeptin-10 and Liraglutide are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose Kisspeptin-10 for Sexual Health. Choose Liraglutide for Fat Loss.
Ready to Learn More?
Looking for trusted sources?